癌症患者18F-FDG PET/CT偶然发现提示COVID-19肺炎:代谢与结构肺改变的关联
该研究回顾了2020年2月19日至5月29日期间接受18F-FDG PET/CT检查的无症状癌症患者,分析提示COVID-19肺炎的偶然发现。CT表现按CO-RADS分类,CO-RADS 5或6者占39%(16/41),其肺浸润SUVmax高于CO-RADS 4及2-3。联合CO-RADS 5或6与SUVmax 2.45诊断时,特异性93.8%(95%CI 71.7%-99.7%),准确率92.9%。
要点
- 无症状癌症患者中,CO-RADS 5或6的肺浸润SUVmax显著更高。
- 联合CO-RADS 5或6与SUVmax 2.45可提高诊断特异性至93.8%。
- 多模态PET/CT可能为高危患者早期诊断提供补充信息。
核心结论
- 在无症状癌症患者中,肺浸润的代谢活性与COVID-19肺炎的多种CT特征性改变密切相关。
- 多模态18F-FDG PET/CT可在疫情期间为部分易感患者的早期诊断提供额外信息。
研究设计与样本
- 回顾性分析2020年2月19日至5月29日期间因癌症接受18F-FDG PET/CT检查的患者。
- 共纳入41例具有提示COVID-19肺炎偶然发现的无症状癌症患者。
- PET图像采用定性(视觉)和半定量(SUVmax测量)分析评估肺部发现。
- CT表现按COVID-19报告和数据系统(CO-RADS)分类为1-6类。
主要发现
- 41例患者中16例(39%)的CT表现被归类为CO-RADS 5或6。
- CO-RADS 5或6患者的SUVmax高于CO-RADS 4患者(6.17 ± 0.82 vs. 3.78 ± 0.50,P = 0.04)。
- CO-RADS 5或6患者的SUVmax高于CO-RADS 2或3患者(6.17 ± 0.82 vs. 3.59 ± 0.41,P = 0.01)。
关键数值与推荐
- 以CO-RADS分类作为金标准,探索肺SUVmax的最佳截断值。
- 联合CO-RADS 5或6与肺浸润SUVmax 2.45时,特异性为93.8%(95% CI,71.7%-99.7%),准确率为92.9%。
临床怎么用
- 对无症状但存在COVID-19肺炎风险的癌症患者,PET/CT偶然发现肺浸润时应结合CO-RADS分类与SUVmax评估。
- 联合CO-RADS 5或6与SUVmax 2.45有助于提高诊断特异性,可作为早期诊断的补充信息。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although the novel coronavirus disease 2019 (COVID-19) can present as nonspecific clinical forms, subclinical cases represent an important route of transmission and a significant source of mortality, mainly in high-risk subpopulations such as cancer patients. A deeper knowledge of the metabolic shift in cells infected with severe acute respiratory syndrome coronavirus 2 could provide new insights about its pathogenic and host response and help to diagnose pulmonary involvement. We explored the potential added diagnostic value of 18F-FDG PET/CT scans in asymptomatic cancer patients with suspected COVID-19 pneumonia by investigating the association between metabolic and structural changes in the lung parenchyma. Methods:18F-FDG PET/CT studies acquired between February 19 and May 29, 2020, were reviewed to identify those cancer patients with incidental findings suggestive of COVID-19 pneumonia. PET studies were interpreted through qualitative (visual) and semiquantitative (measurement of SUVmax) analysis evaluating lung findings. Several characteristic signs of COVID-19 pneumonia on CT were described as COVID-19 Reporting and Data System (CO-RADS) categories (1-6). After comparing the SUVmax of pulmonary infiltrates among different CO-RADS categories, we explored the best potential cutoffs for pulmonary SUVmax against CO-RADS categories as the gold standard result to eliminate the possibility that the diagnosis of COVID-19 pneumonia exists. Results: On multimodal PET/CT imaging, CT signs classified as CO-RADS category 5 or 6 were found in 16 of 41 (39%) oncologic patients. SUVmax was higher in patients with categories 5 and 6 than in patients with category 4 (6.17 ± 0.82 vs. 3.78 ± 0.50, P = 0.04) or categories 2 and 3 (3.59 ± 0.41, P = 0.01). A specificity of 93.8% (95% CI, 71.7%-99.7%) and an accuracy of 92.9% were obtained when combining a CO-RADS score of 5 or 6 with an SUVmax of 2.45 in pulmonary infiltrates. Conclusion: In asymptomatic cancer patients, the metabolic activity in lung infiltrates is closely associated with several combined tomographic changes characteristic of COVID-19 pneumonia. Multimodal 18F-FDG PET/CT imaging could provide additional information during early diagnosis in selected predisposed patients during the pandemic. The prognostic implications of simultaneous radiologic and molecular findings in cancer patients and other subpopulations at high risk for COVID-19 pneumonia deserve further evaluation in prospective research.
引用
- Wakfie-Corieh CG, Ferrando-Castagnetto F, García AMB, et al. Incidental Findings Suggestive of COVID-19 Pneumonia in Oncologic Patients Undergoing 18F-FDG PET/CT Studies: Association Between Metabolic and Structural Lung Changes. J Nucl Med. 2021. PMID: 34088776. doi:10.2967/jnumed.121.261915
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。